<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title> feel  </title>

    <!-- bootstrap css -->
    <link rel="stylesheet" href="asset/css/bootstrap.min.css" />
    <!-- owl-carousel  -->
    <link rel="stylesheet" href="asset/css/owl.carousel.min.css" />
    <!-- main CSS -->
    <link rel="stylesheet" href="asset/css/main.css" />
</head>

<body>
    <!-- ========================= -->
    <!-- header section  -->
    <!-- ========================= -->
    <div class="header-top-cnt blue">
        <p>THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY</p>
    </div>
    <header class="header">
        <nav class="navbar navbar-expand-lg navbar-light p-0">
            <div class="collapse navbar-collapse" id="navbarSupportedContent">
                <ul class="navbar-nav align-items-center me-auto">
                    <li class="nav-item">
                        <a href="home.html" class="header-link">
                            <img src="asset/image/Home-icon.png" alt="" />
                            HOME</a>
                    </li>
                    <li class="nav-item active">
                        <a href="patient_experience.html" class="header-link">
                            <img src="asset/image/Patient-icon.png" alt="" />
                            patient experience</a>
                    </li>
                    <li class="nav-item">
                        <a href="about_brintellix.html" class="header-link">
                            <img src="asset/image/AB_ico.png" alt="" />
                            ABOUT BRINTELLIX</a>
                    </li>
                    <li class="nav-item">
                        <a href="#" class="header-link">
                            <img src="asset/image/AE_icon.png" alt="" />
                            report an adverse Event</a>
                    </li>
                    <li class="nav-item">
                        <a href="#" class="header-link">
                            <img src="asset/image/PI_icon.png" alt="" />
                            prescribing information</a>
                    </li>
                </ul>
            </div>
            
            <a class="navbar-brand logo" href="#"><img src="asset/image/logo.png" alt="" /></a>
            <button id="nav-burger">
                <span></span>
                <span></span>
                <span></span>
                <span></span>
            </button>
        </nav>
        <hr class="divider" />
    </header>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel-sec   ">
        <div class="li">
            <div class="nav-btn">
                <a href="live.html" class="arrow-btn"><img src="asset/image/left-arrow.png" alt=""></a>
                <a href="achieve.html" class="arrow-btn arrow-btn-right"><img src="asset/image/right-arrow.png" alt=""></a>
            </div>
            <figure class="feel-sec-bg">
                <img src="asset/image/feel-sec-bg1.png" alt="" />
            </figure>
            <div class="container">
                <div class="banner-wraper">
                    <p class="major">
                        Brintellix (vortioxetine) is indicated for the treatment of major
                        depressive episodes in adults.1 <br />
                        Prescribing information can be accessed via the tab at the top of
                        this page.
                    </p>
                    <div class="feel-sec-cnt">
                        <h2>I want to FEEL</h2>
                        <figure class="feel-image">
                            <img src="asset/image/feel-sec-img1.png" alt="" />
                        </figure>
                        <h3>
                            Could Brintellix help adult patients like Rebecca diagnosed with
                            MDD who have lost their pleasure in everyday life?
                        </h3>
                    </div>
                </div>
            </div>
            <span class="used">Fictional patients used for illustrative purposes.</span>
            <ul class="dots-body">
                <li class="active"></li>
                <li></li>
                <li></li>
                <li></li>
                <li></li>
            </ul>
        </div>
        
    </section>
    <!-- ========================= -->
    <!-- feelings section  -->
    <!-- ========================= -->
    <section class="feelings cmn-banner">
        <figure class="feelings-bg">
            <img class="feelings-bg1" src="asset/image/feelings-bg2.png" alt="" />
            <img class="display-none" src="asset/image/orange-sm-bg.png" alt="">
        </figure>
        <div class="container">
            <div class="row flex-md-column-reverse flex-sm-column-reverse flex-column-reverse  flex-lg-row">
                <div class="col-lg-6">
                    <div class="feelings-cnt-left">
                        <div class="feelings-top-cnt">
                            <h4>
                                As someone who loves to socialise and meet her friends for
                                coffee, Rebecca should feel excited about catching up with a
                                friend she hasn’t seen in a long time.
                            </h4>
                            <p>
                                But when the day arrived, she felt empty, emotionless, and
                                numb, and she struggled to make the journey to meet her
                                friend.
                            </p>
                            <p>
                                The impact of anhedonia can make it hard for people with
                                depression to enjoy activities that were previously
                                pleasurable.2
                            </p>
                        </div>
                        <div class="defined-cnt">
                            <h4>Anhedonia:</h4>
                            <p>
                                Defined as the lack of enjoyment from, engagement in, or
                                energy for life’s experiences; deficits in capacity to feel
                                pleasure and take interest in things²
                            </p>
                            <p>
                                Anhedonia is a common symptom of MDD reported in up to 75% of
                                depressive patients (n=15/20)³
                            </p>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="feelings-cnt-right">
                        <figure class="round-img">
                            <img src="asset/image/round-img1.png" alt="" />
                        </figure>
                        <h2>
                            Brintellix may help people like Rebecca by reducing feelings of
                            anhedonia vs. baseline⁴
                        </h2>
                        <span class="depressive">MDD, major depressive disorder.  </span>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing section  -->
    <!-- ========================= -->
    <section class="design">
        <div class="container2">
            <div class="row desing-row  ">
                <div class="design-left">
                    <h4>
                        Brintellix may help patients take more pleasure from everyday activities vs baseline⁴
                    </h4>
                    <p>
                        In a post-hoc, open-label study of patients with MDD treated with
                        Brintellix⁴
                    </p>
                    <ul class="both">
                        <li>
                            <span class="week">Both SHAPS and MADRS anhedonia factor scores improved
                                significantly from baseline to week 8 (n=79)</span>
                        </li>
                        <li>
                            <span class="week">Improvements from baseline in anhedonia correlated with
                                improvements from baseline in general function (as measured by
                                SDS) and quality of life (as measured by WHO-5)</span>
                        </li>
                        <li>
                            <span class="week">The results showed that anhedonia improvement was a strong
                                mediator of the association between improvement in depressive
                                symptoms and improvement in social functioning</span>
                        </li>
                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                    data-bs-target="#study-modal">
                    Study design
                </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <div class=" row justify-content-between">
                            <div class="col-lg-4">
                                <span class="change">Change in SHAPS scores from baseline</span>
                            </div>
                            <div class="col-lg-6">
                                <span class="change">Change in MADRS anhedonia factor scores from baseline</span>
                            </div>
                        </div>
                        <figure class="char-img1"><img src="asset/image/chart-img1.png" alt=""></figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Cao B et al. 2019.⁴                            </span>
                            <span class="adapted">SHAPS score was a pre-planned secondary outcome measure. MADRS anhedonia factor consisted of MADRS items: 
                                1 (apparent sadness), 2 (reported sadness), 6 (concentration difficulties), 7 (lassitude), 8 (inability to feel). </span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; SDS, Sheehan Disability Scale; SHAPS, Snaith-Hamilton Pleasure Scale; WHO-5, 5-Item World Health Organization Well-Being Index.</p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing2 section  -->
    <!-- ========================= -->
    <section class="design desing2">
        <div class="container2">
            <div class="emotional">
                <h3>Emotional blunting:</h3>
                <p>Emotional blunting is a condition characterised by a restriction in emotions, which presents clinically as emotional indifference, detachment, reduced responsiveness, low motivation, and apathy⁵
                </p>
                <p>Emotional blunting impacts the day-to-day functioning of patients with MDD5 and was reported by nearly half (46%; n=310/660) of patients receiving a SSRI, SNRI or TCAD for the treatment of MDD⁶                </p>
                <span class="depressant">SNRI, serotonin and noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCAD, tricyclic antidepressant.</span>
            </div>
            <div class="row desing-row flex-lg-row-reverse   ">
                <div class="design-left desing-left2">
                    <h4>
                        50% of patients with MDD reported no emotional blunting at week 8 with Brintellix after switching from an SSRI or SNRI (n=71/143)⁷
                    </h4>
                    <p>
                        In an interventional, 8-week, open-label study of Brintellix:7
                    </p>
                    <ul class="both">
                        <li>
                            <span class="week">Improvements in emotional blunting were observed after just 1 week of treatment as seen on the ODQ scale and MADRS anhedonia factor score</span>
                        </li>
                        <li>
                            <span class="week">Brintellix improved emotional blunting independently of improvements in depressive symptoms</span>
                        </li>
                        <span class="adapted assessed">(Emotional blunting was assessed using the patient-reported ODQ total score)</span>
                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                    data-bs-target="#study-modal1">
                    Study design
                </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="change">Mean change in ODQ domain scores from baseline  (FAS, MMRM; n=143)</span>
                        <figure class="char-img1"><img src="asset/image/chart-img2.png" alt=""></figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Cao B et al. 2019.4</span>
                            <span class="adapted">SHAPS score was a pre-planned secondary outcome measure. MADRS anhedonia factor consisted of MADRS items: 
                                1 (apparent sadness), 2 (reported sadness), 6 (concentration difficulties), 7 (lassitude), 8 (inability to feel). </span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>FAS, full analysis set; ODQ, Oxford Depression Questionnaire; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, Major Depressive Disorder; MMRM, mixed model for repeated measures</p>
            </div>
        </div>
    </section>
        <!-- ========================= -->
    <!-- warnings section  -->
    <!-- ========================= -->
    <section class="warnings">
        <div class="container">
            <div class="warnings-warp">
                <p>
                    For further information about Brintellix, including Tolerability,
                    Special Warnings and Precautions and Contraindications, please visit
                    the About Brintellix Section
                </p>
                <button class="btn-more about-btn">about brintellix</button>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- deserve section  -->
    <!-- ========================= -->
    <section class="deserve">
        <div class="container">
            <div class="deserve-wrap">
                <h3>
                    Explore more in the sections below:
                </h3>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel">
        <ul class="feel-body">
            <li class="light-orange">
                <h4>
                    I want to <br />
                    FEEL
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img1.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in anhedonia and emotional blunting</p>
                </div>
                <a href="feel.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-2">
                <h4>
                    I want to
                    <br />
                    ACHIEVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img2" src="asset/image/feel-img2.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in work productivity, presenteeism and functioning</p>
                </div>
                <a href="achieve.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-3">
                <h4>
                    I want to <br />
                    MOVE FORWARD
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img3.png" alt="" />
                </figure>
                <div class="function">
                    <p>
                        Brintellix in patients with MDD together with anxiety and a
                        history of trauma
                    </p>
                </div>
                <a href="forward.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-4">
                <h4>
                    I want to <br />
                    FOCUS
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img4.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in cognition</p>
                </div>
                <a href="focus.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-5">
                <h4>
                    I want to <br />
                    MAINTAIN
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img5.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in remission and relapse</p>
                </div>
                <a href="maintain.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-6">
                <h4>
                    I want to <br />
                    LIVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img6.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix and sexual functioning</p>
                </div>

                <a href="live.html" class="btn-more btn-more-2">MORE</a>
            </li>
        </ul>
    </section>
    <!-- ========================= -->
    <!-- reference   section  -->
    <!-- ========================= -->
    <section class="reference">
        <div class="container">
            <div class="reference-wrap">
                <div class="adverse-blk">
                    <span class="events">Adverse events should be reported.
                    </span>
                    <p>Reporting forms and information can be found at <a href="#"
                            class="yellowcard">www.mhra.gov.uk/yellowcard</a> Adverse events should
                        also be reported to Lundbeck Limited, Medical Information, on: <a class="mobile-number" href="tel:01908 638972">01908 638972</a> or Email:
                        <a href="mailto:SafetyLuUnitedKingdom@lundbeck.com" class="yellowcard"> SafetyLuUnitedKingdom@lundbeck.com</a>
                        
                    </p>
                    
                </div>
                <div class="reference-cnt">
                    <span class="ref-head">References</span>
                    <ul class="reference-list">
                        <li>
                            <span>Lundbeck. Brintellix. Summary of Product Characteristics GB and NI.</span>
                        </li>
                        <li>
                            <span>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition, Text Revision (DSM-5-TR). 2022. https://doi.org/10.1176/appi.books.9780890425787.  
                            </span>
                        </li>
                        <li>
                            <span>Franken IHA, et al. Journal of Affective Disorders. 2007 Sep 20;99(1-3):83-89. 
                            </span>
                        </li>
                        <li>
                            <span>Cao B et al. Front Psychiatry 2019;10:17. 
                            </span>
                        </li>
                        <li>
                            <span>Price J and Goodwin GM et al. Medicographia 2009;31:152–156. 
                            </span>
                        </li>
                        <li>
                            <span>Goodwin GM et al. J Affect Disord 2017;221:31-35.
                            </span>
                        </li>
                        <li>
                            <span>Fagiolini A et al. J Affect Disord 2021;283:472–479. </span>
                        </li>
                        <li>
                            <span>Price J, et al. J Affect Disord. 2012 September;140(1):66-74.</span>
                        </li>
                    </ul>
                    <span class="ref-head">UK-BRIN-1280 | June 2023</span>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- footer   section  -->
    <!-- ========================= -->
    <footer>
        <hr class="footer-divider" />
        <div class="container">
            <div class="row">
                <div class="footer-log d-flex">
                    <a href="#" class="footer-logo"><img src="asset/image/footer-logo.png" alt="" /></a>
                </div>
                <div class="location">
                    <p>
                        Lundbeck Limited <br />
                        Iveco House, Station Road <br />
                        Watford, Hertfordshire <br />
                        WD17 1ET <br />
                        United Kingdom
                    </p>
                    <span class="ref-head">UK-BRIN-1360 | June 2023</span>
                </div>
                <div class="contact">
                    <span class="ref-head">Contact us </span>
                    <a class="mail-link" href="tel:+44 1908 649 966">+44 1908 649 966</a>
                    <a href="mailto:united_kingdom@lundbeck.com" class="mail-link">united_kingdom@lundbeck.com</a>
                </div>
                <div class="footer-link-cnt">
                    <span class="ref-head">Links</span>
                    <ul class="footer-links">
                        <li><a href="#" class="footer-link">Contact us </a></li>
                        <li><a href="#" class="footer-link">Terms of Use</a></li>
                        <li>
                            <a href="#" class="footer-link">Report an Adverse Event</a>
                        </li>
                        <li>
                            <a href="#" class="footer-link">Website Privacy Policy</a>
                        </li>
                        <li><a href="#" class="footer-link">Cookies settings</a></li>
                        <li>
                            <a href="#" class="footer-link">Prescribing information </a>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </footer>

    <!----------------------- JQUERY ----------------->
    <script src="asset/js/jquery-min.js"></script>

    <!-- BOOTSTRAP JS -->
    <script src="asset/js/bootstrap.bundle.min.js"></script>
    <!----------------------- OWL CAROUSEL ----------------->
    <script src="asset/js/owl.carousel.min.js"></script>
    <!-- script js -->
    <script src="asset/js/script.js"></script>
    <!--study 1  Modal -->
    <div class="modal fade" id="study-modal" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span>Cao B et al. 2019¹</span>
                    <h3>A post-hoc analysis of a primary study of the effects of 8 weeks’ Brintellix (10–20 mg) treatment in patients (18–65 years) with major depressive disorder (MDD). The primary outcome measure was improvement from baseline in anhedonia,* which (like cognition) is an important mediator of overall clinical improvement.</h3>
                    <p>Study objective: To evaluate the anti-anhedonia effects of Brintellix, and to assess the extent to which improvements in anhedonia correlate with overall function and quality of life.</p>
                    <div class="row m-0">
                        <div class=" primary-outcome">
                            <span class="key">Key inclusion criteria</span>
                            <p>
                                Patients 18–65 years of age with a current primary diagnosis of MDD per DSM-5 and a current depressive episode (MDE). Patients had MADRS total score ≥20 (depression severity) and history of at least one prior MDE.</p>
                                <p>Subjects underwent five visits. The MADRS total score was evaluated at all five, and the SHAPS and SDS scores were evaluated at three different time points.</p>
                        </div>
                        <div class="  blue-side">
                            <figure class="white-arrow"><img src="asset/image/white-arrow.png" alt=""></figure>
                            <div class="least">
                                <span class="score">Patients with MDD and a current MDE <br>
                                    (MADRS total score ≥20 and at least one prior MDE)</span>
                                    <figure class="chart-img3"><img src="asset/image/chart-img3.png" alt=""></figure>
                            </div>
                        </div>
                    </div>
                    <div class="row justify-content-between p-0">
                        <div class="col-lg-6">
                            <span class="  outcome"><strong>Primary outcome:</strong> Change in anhedonia, as measured by the baseline to endpoint change in SHAPS and MADRS anhedonia factor.
                            </span>
                        </div>
                        <div class="col-lg-6">
                            <span class="  outcome"><strong>Secondary outcomes:</strong> Functional impairment measured by SDS, quality of life measured by the WHO-5.

                            </span>
                        </div>
                    </div>
                    <div class="licensed">
                        <span>*Anhedonia, the decreased ability to feel pleasure, particularly in activities they used to enjoy.
                        </span>
                        <span>The licensed starting dose of Brintellix for patients aged 65 or over is 5 mg/day. </span>
                        <p>DSM-5, Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; MDE, major depressive episode; SDS, Sheehan Disability Scale; SHAPS, Snaith-Hamilton Pleasure Scale; WHO-5, 5-item World Health Organization Well-being Index.
                        </p>
                        <p><strong>Reference:</strong> 1. Cao B, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Frontiers in psychiatry. 2019 Jan 31;10:17. </p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1280 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <!--study 2  Modal -->
    <div class="modal fade" id="study-modal1" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span>Fagiolini A et al. 2021¹</span>
                    <h3>An interventional, 8-week, open-label, flexible-dose (10-20 mg) study of Brintellix on emotional blunting in major depressive disorder (MDD) patients with partial response to SSRI/SNRI treatment.</h3>
                    <p> Study objective: Assess the efficacy of Brintellix on emotional blunting in patients with partial response to prior treatment of SSRIs/SNRIs.</p>
                    <div class="row m-0 r1">
                        <div class=" primary-outcome primary-outcome2">
                            <span class="key">Key inclusion criteria</span>
                            <p>
                                Patients 18-65 years of age with a primary diagnosis of MDD per DSM-5 and a current depressive episode of 12 months’ duration, with partial response to an SSRI/SNRI monotherapy at approved doses for ≥6 weeks prior to the screening visit. Patients had a MADRS total score >21 and 29 (depression severity) and ODQ total score ≥50 at baseline, and subjective confirmation of emotional blunting by standardised screening question. </p>
                                <p>Screening question: “Emotional effects vary, but may include, for example, feeling emotionally ‘numbed’ or ‘blunted’ in some way; lacking positive emotions or negative emotions; feeling detached from the world around you; or ‘just not caring’ about things that you used to care about. Have you experienced such emotional effects during the last 6 weeks?”</p>
                                <p>Clinical and safety assessments were conducted at baseline (except for the CGI-I) and at Week 1, Week 4 and Week 8.</p>
                                <p>150 patients were treated, of whom 143 (95.3%) were included in the clinical analyses.</p>

                        </div>
                        <div class="  blue-side blue-side2">
                            <figure class="white-arrow white-arrow2"><img src="asset/image/white-arrow2.png" alt=""></figure>
                            <div class="least least2">
                                <div class="white-arrow-cnt">
                                    <span class="font-size-16">Open-label period</span>
                                    <figure class="white-lg-arrow"><img src="asset/image/white-lg-arrow.png" alt=""></figure>
                                </div>
                                    <figure class="chart-img3"><img src="asset/image/chart-img4.png" alt=""></figure>
                            </div>
                        </div>
                    </div>
                    <div class="row justify-content-between p-0">
                        <div class="col-lg-6">
                            <span class="  outcome"><strong>Primary outcome:</strong> Emotional blunting assessed by mean change from Week 0 to Week 8 in ODQ total score using a mixed model for repeated measures (MMRM) including site and week as fixed effects, the baseline score as a continuous covariate and the baseline score-by-week interaction.
                            </span>
                        </div>
                        <div class="col-lg-6">
                            <span class="  outcome"><strong>Secondary outcomes:</strong> Measures of depressive symptoms (MADRS), motivation and energy (MEI), psychosocial functioning (SDS), and cognitive performance (DSST).
                            </span>
                            <span class="  outcome"><strong>Tolerability:</strong> The most common treatment-emergent adverse events included nausea, headache, dizziness, vomiting, and diarrhoea.
                            </span>
                        </div>
                    </div>
                    <div class="licensed">
                        <span>*Anhedonia, the decreased ability to feel pleasure, particularly in activities they used to enjoy.
                        </span>
                        <span>The licensed starting dose of Brintellix for patients aged 65 or over is 5 mg/day. </span>
                        <p>DSM-5, Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; MDE, major depressive episode; SDS, Sheehan Disability Scale; SHAPS, Snaith-Hamilton Pleasure Scale; WHO-5, 5-item World Health Organization Well-being Index.
                        </p>
                        <p><strong>Reference:</strong> 1. Cao B, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Frontiers in psychiatry. 2019 Jan 31;10:17. </p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1280 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
</body>

</html>